DOCSLIB.ORG

Resident Bibliography

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Resident Bibliography BIBLIOGRAPHY 2020-2021 INTERNAL MEDICINE RESIDENCY PROGRAM UNIVERSITY OF MARYLAND Peer Reviewed Publications (75) 1. Rauf MS, Khan ZA, Zahir MN, Al-Sweedan S, Al-Kofide A, Alharthy H, Almugbel FA, Osmani A, Elhassan TAM, Khafaga Y, Maghfoor I, Akhtar S. Comparison of 18F-Labelled Fluoro-2-Deoxyglucose-PET with Conventional Computed Tomography for Staging and Response Assessment in Paediatric and Adult Patients with Nodular Lymphocyte- Predominant Hodgkin's Lymphoma. Nucl Med Commun. 2021 Apr 9. doi: 10.1097/MNM.0000000000001406. Epub ahead of print. PMID: 33852535. 2. Alhassan E, Otaishan D, Aljohani S, Almubarak M. Massive Right Ventricular Thrombus Secondary to Catastrophic Antiphospholipid Syndrome. J Clin Rheumatol. 2021 Mar 1;27(2):e77-e78.PMID: 31985720 3. Khawaja MN, Alhassan E, Bilal J, Jatwani S, Mehta B, Bhalla V, Morgan DJ, Siaton BC, Hochberg MC. Medical overuse of therapies and diagnostics in rheumatology. Clin Rheumatol. 2021 Feb 10. doi: 10.1007/s10067-021-05638-2. PMID: 33569709. 4. Alhassan E, Gendelman HK, Sabha MM, Hawkins-Holt M, Siaton BC. Bilateral retinal vasculitis as the first presentation of systemic lupus erythematosus. Am J Case Rep. 2021 April 6. DOI: 10.12659/AJCR.930650. PMID: 33935278. 5. Vallabhaneni S, Kichloo A, Amir R, Aljadah M, Albosta M, Singh J, C Cuttita C. Transbronchial Needle Aspiration Cytology and Purulent Pericarditis. J Investig Med High Impact Case Rep. 2020;8;232470962095134. doi:10.1177/2324709620951345. 6. Amir R, Kichloo A, Aljadah M, Kanjwal K. Arrhythmias and COVID 19. Am J Ther. 2020 Dec 7. doi: 10.1097/MJT.0000000000001288. Epub ahead of print. PMID: 33298748. 7. Kichloo A, Amir R, Wani F, Randhawa S, Rudd B, Rechlin D. Anticoagulation and antiplatelet therapy in contact sports: is it career limiting? J Investig Med. 2020 Dec 22:jim- 2020-001658. doi: 10.1136/jim-2020-001658. Epub ahead of print. PMID: 33443051. 8. Kichloo A, Kumar A, Amir R, Aljadah M, Farooqi N, Albosta M, Singh J, Jamal S, El-Amir Z, Kichloo A, Lone N. Utilization of extracorporeal membrane oxygenation during the COVID- 19 pandemic. World J Crit Care Med. 2021 Jan 9;10(1):1-11. doi: 10.5492/wjccm.v10.i1.1. PMID: 33505868. 9. Wani F, Amir R, Aljadah M, Albosta M, Guidi JC, Singh J, Kanjwal K, Kichloo A. Implantable cardiac devices in geriatric patients: a primer for primary and geriatric physicians. Rev Cardiovasc Med. 2021 Mar 30;22(1):39-50. doi: 10.31083/j.rcm.2021.01.222. PMID: 33792247. 10. Amirahmadi R, Childress C, Patel S, Wagner L. Electric cigarette-related lung injury and cardiovascular insult, BMJ Case Rep, 14(3):e238352. March 2021. doi: 10.1136/bcr-2020- 238352. PMID: 33674290. 1 11. Bazarbashi N, Kapadia SR, Nicholls SJ, Carlo J, Gad MM, Kaur M, Karrthik A, Sammour YM, Diab M, Ahuja KR, Tuzcu EM, Nissen SE, Puri R. Oral Calcium Supplements Associate With Serial Coronary Calcification: Insights From Intravascular Ultrasound. JACC Cardiovasc Imaging. 2021 Jan;14(1):259-268. doi: 10.1016/j.jcmg.2020.06.030. Epub 2020 Aug 19. PMID: 32828785. 12. Bazarbashi N, Miller M. Icosapent Ethyl: Niche Drug or for the Masses? Curr Cardiol Rep. 2020 Aug 8;22(10):104. doi: 10.1007/s11886-020-01356-4. PMID: 32770402. 13. Sammour Y, Krishnaswamy A, Kumar A, Puri R, Tarakji KG, Bazarbashi N, et al. Incidence, Predictors, and Implications of Permanent Pacemaker Requirement After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2021 Jan 25;14(2):115-134. doi: 10.1016/j.jcin.2020.09.063. PMID: 33478630. 14. Saad AM, Kassis N, Gad MM, Abdelfattah O, Ahuja KR, Farwati M, Isogai T, Bazarbashi N, et al. Impact of atrial fibrillation on outcomes following MitraClip: A contemporary population-based analysis. Catheter Cardiovasc Interv. 2021 May 1;97(6):1252-1256. doi: 10.1002/ccd.29310. Epub 2020 Oct 5. PMID: 33016645. 15. Nazir S, Ahuja KR, Virk HUH, Changal K, Soni RG, Shekhar S, Kaur M, Bazarbashi N, Ramanathan PK, Gupta R. Comparison of Outcomes of Transcatheter Mitral Valve Repair (MitraClip) in Patients <80 Years Versus ≥80 Years. Am J Cardiol. 2020 Sep 15;131:91-98. doi: 10.1016/j.amjcard.2020.06.050. Epub 2020 Jun 30. PMID: 32718547. 16. Cravero AL, Kim NJ, Feld LD, Berry K, Rabiee A, Bazarbashi N, et al. Impact of exposure to patients with COVID-19 on residents and fellows: an international survey of 1420 trainees. Postgrad Med J. 2020 Oct 21:postgradmedj-2020-138789. doi: 10.1136/postgradmedj-2020- 138789. Epub ahead of print. PMID: 33087533. 17. Farwati M, Wazni O, Diab M, Scandinaro A, Amin M, Zmaili M, Bazarbashi N, et al. (2021) Super and Non responders to catheter ablation for Afib: A Quality of Life Assessment using patient reported outcomes. Circulation: Arrythmia and Electrophysiology. Accepted 05/18/2021. 18. Theppote AS, Carmack AE, Riedel DJ. False positive HIV testing after T-cell receptor therapy. AIDS. 2020 Jun 1;34(7):1103-1105. doi: 10.1097/QAD.0000000000002511. PMID: 32379161. 19. Pandit RR, Wibblesman TD, Considine SP, Jenkins TL, Xu D, Levin HJ, Obeid A, Ho AC. Distribution and practice patterns of retina providers in the United States. Ophthalmology. 2020 Nov;127:1580-1581. doi: 10.1016/j.opthha.2020.04.016. PMID 32473740. 20. Wade CI, Couperus-Mashewske CJ, Geurts ME, Derfler N, Ngo J, Couperus KS. Respiratory failure due to a large mediastinal mass in a 4-year-old female with blast cell crisis: A case report. Clin Pract Cases Emerg Med. 2020 Aug;4(3):400-403. doi: 10.5811/cpcem.2020.5.47016. PMID 32926696. 21. Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB, Warner AC, Schweitzer C, Doran SL, Korrapati S, Stevanovic S, Trimble CL, Kanakry JA, Bagheri MH, Ferraro E, Astrow SH, Bot A, Faquin WC, Stroncek D, GKitsas N, Highfill S, Hinrichs CS. 2 TCR-engineered T-cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med. 2021 Mar;27(3):419-425. doi: 10.1038/s41591-020-01225-1. 22. Lutfi F, Benyounes A, Farrukh N, Bork J, Duong V. Agranulocytosis following COVID-19 Recovery. Cureus. 2020 Jul 29;12(7)e:9463. doi: 10.7759/cureus.9463. PMID 32874794. 23. Cires-Drouet RS, Nagarsheth K, Kaczorowski DJ, Toursvadkohi S, Deatrick K, Madathil RJ, Jones KM, Liskov S, Fitch J, Sayad M, Pasrija C, Mayorga-Carlin M, Herr D, Sorkin JD, Griffith B, Lal BK, Gammie JS. Catheter-based interventions versus medical and surgical approaches in acute pulmonary embolism. J Vasc Surg Venous Lymphat Disord. 2021 May 7;S2213-333X(21)00101-3. Doi: 10.1016/j.jvsv.2021.02.015. PMID 33965609. 24. Lutfi F, Siglin J, Sanchez-Petitto G, Bukhari A, Gottlieb D, Kim DW, Cooper B, Fleyshman M, Perez DM, Kleinberg M, Lapidus RG, Rapoport AP, Fan A, Dahiya S. Detailed Immunophenotypic Profiling of Peripheral Blood Immune Cells in Patients with Hematologic Malignancies after Sars-Cov-2 Infection. Blood 2020; 136 (1): 32. doi: 10.1182/blood-2020- 143160. 25. Gendelman HK, Sabha M, Gryaznov AA, Siaton BC. Recurrent Syncope Due to Concurrent Cardiac Sarcoidosis and Large-Vessel Vasculitis. Am J Case Rep. 2021 Jan 29;22:e927331. doi: 10.12659/AJCR.927331. PMID: 33510124. 26. Harringa JB, Bracken RL, Markhardt BK, Ziemlewicz TJ, Lubner M, Chiu A, Birstler J, Pickhardt PJ, Reeder SB, Repplinger MD. Magnetic resonance imaging versus computed tomography and ultrasound for the diagnosis of female pelvic pathology. Emerg Radiol. 2021 March 17. Doi: 10.1007/s10140-021-01923-4. PMID 32763381. 27. Guo L, Torii S, Fernandez R, Braumann RE, Fuller DT, Paek KH, Gadhoke NV, Maloney KA, Harris K, Mayhew CM, Zarpak R, Stevens LM, Gaynor BJ, Jinnouchi H, Sakamoto A, Sato Y, Mori H, Kutyna MD, Lee PJ, Weinstein LM, Collado-Rivera CJ, Ali BB, Atmakuri DR, Dhingra R, Finn ELB, Bell MW, Lynch M, Cornelissen A, Kuntz SH, Park JH, Kutys R, Park JE, Wang L, Hong SN, Gupta A, Hall JL, Kolodgie FD, Romero ME, Jeng LJB, Mitchell BD, Surve D, Fowler DR, Hong CC, Virmani R, Finn AV. Genetic Variants Associated With Unexplained Sudden Cardiac Death in Adult White and African American Individuals. JAMA Cardiol. 2021 Jun 2. doi: 10.1001/jamacardio.2021.1573. Epub ahead of print. PMID: 34076677. 28. Deitte LA, Mian AZ, Esfahani SA, Hu JY. Going virtual: Redesigning the interview experience. J Am Coll Radiol. 2021 Feb;18:337-339. doi:10.1016/j.jacr.2020.06.021. PMID 32673575. 29. Esfahani SA, Lee A, Hu JY, Kelly M, Magudia K, Evertt C Szabunio M, Ackerman S, Spalluto LB. Challenges faced by women in radiology during the pandemic -A summary of the AAWR Women’s Caucus at the ACR 2020 annual meeting. Clin Imaging. 2020 Dec; 68:291-294. Doi 10.1016/j.clinimag.2020.08.016. PMID 32957024. 30. Hu JY, Bergquist PJ, Hossain R, Ropp AM, Kligerman S, Amin SB, Sechrist JW, Patel P, Judy J, White CS. Interobserver reliability of the coronary artery disease reporting and data system in clinical practice. J Thorac Imaging. 2021 Mar 1;36:95-101. Doi:10.1097/RT.0000000000000503. PMID 32205820. 3 31. Iqbal T and Miller M. VITAL, REDUCE-IT, STRENGTH, and Beyond: Putting omega 3 fatty acids into practice in 2021. Curr Card Rep. (Accepted for publication) 32. Kashanian SM, Li AY, Mustafa Ali M, Sutherland ME, Duong VH, Hambley BC, Zacholski K, El Chaer F, Holtzman NG, Imran M, Patzke CL, Cornu J, Duffy A, Dezern AE, Gojo I, Norsworthy KJ, Levis MJ, Smith BD, Baer MR, Ghiaur G, Emadi A. Increased body mass index is a risk factor for acute promyelocytic leukemia.
Load more

Recommended publications
  • Thrombosis in the Antiphospholipid Syndrome
    Thrombosis in the antiphospholipid syndrome Reyhan D‹Z KÜÇÜKKAYA Division of Hematology, Department of Internal Medicine, Istanbul University, Istanbul School of Medicine, Istanbul, TURKEY Turk J Hematol 2006;23(1): 5-14 INTRODUCTION her autoimmune disorders, especially with systemic lupus erythematosus (SLE)[8]. Besi- Antiphospholipid antibodies (aPLA) are des these autoimmune conditions, aPLA may heterogenous antibodies directed against be present in healthy individuals, in patients phospholipid–protein complexes. Antiphosp- with hematologic and solid malignancies, in holipid syndrome (APS) is diagnosed when ar- patients with certain infections [syphilis, lep- terial and/or venous thrombosis or recurrent rosy, human immunodeficiency virus (HIV), fetal loss occurs in a patient in whom scre- cytomegalovirus (CMV), Epstein-Barr virus ening for aPLA are positive. Because both (EBV), etc.], and in patients being treated thrombosis and fetal loss are common in the with some drugs (phenothiazines, procaina- population, persistent positivity of aPLA is mide, phenytoin etc.). Those antibodies are important. This syndrome is predominant in defined as “alloimmune aPLA”, and they are females (female to male ratio is 5 to 1), espe- generally transient and not associated with cially during the childbearing years[1-7]. the clinical findings of APS[9]. A minority of As in the other autoimmune disorders, APS patients may acutely present with mul- aPLA and APS may accompany other autoim- tiple simultaneous vascular occlusions affec- mune diseases and certain situations. APS is ting small vessels predominantly, and this is referred to as “primary” when it occurs alone termed as “catastrophic APS (CAPS)”[1-7]. or “secondary” when it is associated with ot- Milestones in the Antiphospholipid Syndrome History Antifosfolipid sendromu The first antiphospholipid antibodies we- Anahtar Kelimeler: Antifosfolipid sendromu, Antifosfolipid re discovered by Wasserman et al.[10] in antikorlar, Tromboz.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub
    US 2010O2.10567A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub. Date: Aug. 19, 2010 (54) USE OF ATUFTSINASATHERAPEUTIC Publication Classification AGENT (51) Int. Cl. A638/07 (2006.01) (76) Inventor: Dorian Bevec, Germering (DE) C07K 5/103 (2006.01) A6IP35/00 (2006.01) Correspondence Address: A6IPL/I6 (2006.01) WINSTEAD PC A6IP3L/20 (2006.01) i. 2O1 US (52) U.S. Cl. ........................................... 514/18: 530/330 9 (US) (57) ABSTRACT (21) Appl. No.: 12/677,311 The present invention is directed to the use of the peptide compound Thr-Lys-Pro-Arg-OH as a therapeutic agent for (22) PCT Filed: Sep. 9, 2008 the prophylaxis and/or treatment of cancer, autoimmune dis eases, fibrotic diseases, inflammatory diseases, neurodegen (86). PCT No.: PCT/EP2008/007470 erative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the S371 (c)(1), present invention relates to pharmaceutical compositions (2), (4) Date: Mar. 10, 2010 preferably inform of a lyophilisate or liquid buffersolution or artificial mother milk formulation or mother milk substitute (30) Foreign Application Priority Data containing the peptide Thr-Lys-Pro-Arg-OH optionally together with at least one pharmaceutically acceptable car Sep. 11, 2007 (EP) .................................. O7017754.8 rier, cryoprotectant, lyoprotectant, excipient and/or diluent. US 2010/0210567 A1 Aug. 19, 2010 USE OF ATUFTSNASATHERAPEUTIC ment of Hepatitis BVirus infection, diseases caused by Hepa AGENT titis B Virus infection, acute hepatitis, chronic hepatitis, full minant liver failure, liver cirrhosis, cancer associated with Hepatitis B Virus infection. 0001. The present invention is directed to the use of the Cancer, Tumors, Proliferative Diseases, Malignancies and peptide compound Thr-Lys-Pro-Arg-OH (Tuftsin) as a thera their Metastases peutic agent for the prophylaxis and/or treatment of cancer, 0008.
    [Show full text]
  • Subset of Alphabetical Index to Diseases and Nature of Injury for Use with Perinatal Conditions (P00-P96)
    Subset of alphabetical index to diseases and nature of injury for use with perinatal conditions (P00-P96) SUBSET OF ALPHABETICAL INDEX TO DISEASES AND NATURE OF INJURY FOR USE WITH PERINATAL CONDITIONS (P00-P96) Conditions arising in the perinatal period Conditions arising—continued - abnormal, abnormality—continued Note - Conditions arising in the perinatal - - fetus, fetal period, even though death or morbidity - - - causing disproportion occurs later, should, as far as possible, be - - - - affecting fetus or newborn P03.1 coded to chapter XVI, which takes - - forces of labor precedence over chapters containing codes - - - affecting fetus or newborn P03.6 for diseases by their anatomical site. - - labor NEC - - - affecting fetus or newborn P03.6 These exclude: - - membranes (fetal) Congenital malformations, deformations - - - affecting fetus or newborn P02.9 and chromosomal abnormalities - - - specified type NEC, affecting fetus or (Q00-Q99) newborn P02.8 Endocrine, nutritional and metabolic - - organs or tissues of maternal pelvis diseases (E00-E99) - - - in pregnancy or childbirth Injury, poisoning and certain other - - - - affecting fetus or newborn P03.8 consequences of external causes (S00-T99) - - - - causing obstructed labor Neoplasms (C00-D48) - - - - - affecting fetus or newborn P03.1 Tetanus neonatorum (A33) - - parturition - - - affecting fetus or newborn P03.9 - ablatio, ablation - - presentation (fetus) (see also Presentation, - - placentae (see also Abruptio placentae) fetal, abnormal) - - - affecting fetus or newborn
    [Show full text]
  • Mortality Perinatal Subset, 2013
    ICD-10 Mortality Perinatal Subset (2013) Subset of alphabetical index to diseases and nature of injury for use with perinatal conditions (P00-P96) Conditions arising in the perinatal period Note - Conditions arising in the perinatal period, even though death or morbidity occurs later, should, as far as possible, be coded to chapter XVI, which takes precedence over chapters containing codes for diseases by their anatomical site. These exclude: Congenital malformations, deformations and chromosomal abnormalities (Q00-Q99) Endocrine, nutritional and metabolic diseases (E00-E99) Injury, poisoning and certain other consequences of external causes (S00-T99) Neoplasms (C00-D48) Tetanus neonatorum (A33 2a) A -ablatio, ablation - - placentae (see alsoAbruptio placentae) - - - affecting fetus or newborn P02.1 2a -abnormal, abnormality, abnormalities - see also Anomaly - - alphafetoprotein - - - maternal, affecting fetus or newborn P00.8 - - amnion, amniotic fluid - - - affecting fetus or newborn P02.9 - - anticoagulation - - - newborn (transient) P61.6 - - cervix NEC, maternal (acquired) (congenital), in pregnancy or childbirth - - - causing obstructed labor - - - - affecting fetus or newborn P03.1 - - chorion - - - affecting fetus or newborn P02.9 - - coagulation - - - newborn, transient P61.6 - - fetus, fetal 1 ICD-10 Mortality Perinatal Subset (2013) - - - causing disproportion - - - - affecting fetus or newborn P03.1 - - forces of labor - - - affecting fetus or newborn P03.6 - - labor NEC - - - affecting fetus or newborn P03.6 - - membranes
    [Show full text]
  • Lupus Anticoagulant‑Hypoprothrombinemia Syndrome and Immunoglobulin‑A Vasculitis: a Report of Japanese Sibling Cases and Review of the Literature
    Rheumatology International (2019) 39:1811–1819 Rheumatology https://doi.org/10.1007/s00296-019-04404-7 INTERNATIONAL CASES WITH A MESSAGE Lupus anticoagulant‑hypoprothrombinemia syndrome and immunoglobulin‑A vasculitis: a report of Japanese sibling cases and review of the literature Kaori Fujiwara1 · Junya Shimizu3 · Hirokazu Tsukahara1 · Akira Shimada2 Received: 6 March 2019 / Accepted: 29 July 2019 / Published online: 7 August 2019 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is a rare bleeding disorder caused by antiprothrombin anti- bodies. LAHPS is associated with systemic lupus erythematosus (SLE) or infections. We describe two Japanese brothers with immunoglobulin-A vasculitis (IgAV) who met the diagnostic criteria of LAHPS. They presented with palpable purpura and abdominal pain, and had a prolonged activated partial thromboplastin time (APTT) and prothrombin defciency with the presence of lupus anticoagulant. Pediatric LAHPS was reviewed in abstracts from the Japan Medical Abstracts Society that were written in Japanese and PubMed or Web of Science-listed articles in English between 1996 and 2019. Including our cases, pediatric LAHPS has been reported in 40 Japanese and 46 non-Japanese patients. We summarized the clinical and laboratory characteristics of all 86 cases, and found only one Japanese LAHPS case with IgAV, except for our cases. Of the 86 cases, most were associated with infections followed by SLE. The presence of SLE, older age, lower prothrombin levels, severe bleeding symptoms, and positivity of immunoglobulin G anticardiolipin antibodies and anticardiolipin/β2-glycoprotein I antibodies and/or β2-glycoprotein I-dependent anticardiolipin antibodies had higher odds of requiring treatment.
    [Show full text]
  • Propylthiouracil Tablets, Usp
    PROPYLTHIOURACIL TABLETS, USP WARNING Severe liver injury and acute liver failure, in some cases fatal, have been reported in patients treated with propylthiouracil. These reports of hepatic reactions include cases requiring liver transplantation in adult and pediatric patients. Propylthiouracil should be reserved for patients who cannot tolerate methimazole and in whom radioactive iodine therapy or surgery are not appropriate treatments for the management of hyperthyroidism. Propylthiouracil may be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimester of pregnancy (see Warnings and Precautions). DESCRIPTION Propylthiouracil is one of the thiocarbamide compounds. It is a white, crystalline substance that has a bitter taste and is very slightly soluble in water. Propylthiouracil is an antithyroid drug administered orally. The structural formula is: Each tablet contains propylthiouracil 50 mg and the following inactive ingredients: corn starch, docusate sodium, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium benzoate, and sodium starch glycolate. CLINICAL PHARMACOLOGY Propylthiouracil inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. The drug does not inactivate existing thyroxine and triiodothyronine that are stored in the thyroid or circulating in the blood, nor does it interfere with the effectiveness of thyroid hormones given by mouth or by injection. Propylthiouracil inhibits the conversion of thyroxine
    [Show full text]
  • Alphabetical Index to Diseases and Nature of Injury for Use with Perinatal Conditions (P00-P96)
    Subset of alphabetical index to diseases and nature of injury for use with perinatal conditions (P00-P96) SUBSET OF ALPHABETICAL INDEX TO DISEASES AND NATURE OF INJURY FOR USE WITH PERINATAL CONDITIONS (P00-P96) Conditions arising in the perinatal period Conditions arising—continued - abnormal, abnormality—continued Note - Conditions arising in the perinatal - - fetus, fetal period, even though death or morbidity occurs - - - causing disproportion later, should, as far as possible, be coded to - - - - affecting fetus or newborn P03.1 chapter XVI, which takes precedence over - - forces of labor chapters containing codes for diseases by - - - affecting fetus or newborn P03.6 their anatomical site. - - labor NEC - - - affecting fetus or newborn P03.6 These exclude: - - membranes (fetal) Congenital malformations, deformations - - - affecting fetus or newborn P02.9 and chromosomal abnormalities - - - specified type NEC, affecting fetus or (Q00-Q99) newborn P02.8 Endocrine, nutritional and metabolic - - organs or tissues of maternal pelvis diseases (E00-E99) - - - in pregnancy or childbirth Injury, poisoning and certain other - - - - affecting fetus or newborn P03.8 consequences of external causes (S00-T99) - - - - causing obstructed labor Neoplasms (C00-D48) - - - - - affecting fetus or newborn P03.1 Tetanus neonatorum (A33) - - parturition - - - affecting fetus or newborn P03.9 - ablatio, ablation - - presentation (fetus) (see also Presentation, - - placentae (see also Abruptio placentae) fetal, abnormal) - - - affecting fetus or newborn P02.1
    [Show full text]
  • Congenital Chikungunya Virus Infection After an Outbreak in Salvador, Bahia, Brazil
    THIEME Case Report e299 Congenital Chikungunya Virus Infection after an Outbreak in Salvador, Bahia, Brazil Priscila Pinheiro Ribeiro Lyra, MD1 Gúbio Soares Campos, PhD2 Igor Dórea Bandeira1 Silvia Ines Sardi, PhD2 Lilian Ferreira de Moura Costa, PhD2 Flávia Rocha Santos2 Carlos Alexandre Santos Ribeiro, MD1 Alena Maria Barreto Jardim, MD1 Ana Cecília Travassos Santiago, MD1 Patrícia Maria Ribeiro de Oliveira, MD1 Lícia Maria Oliveira Moreira, MD1 1 Department of Pediatrics, Climério de Oliveira Maternity, Federal Address for correspondence Priscila Pinheiro Ribeiro Lyra, MD, University of Bahia School of Medicine, Bahia, Brazil Department of Pediatrics, Universidade Federal da Bahia, Avenue 2 Laboratory of Virology, Health Science Institute, Federal University of Reitor Miguel Calmon S/N, Canela Salvador–BA, Salvador, Bahia 40110- Bahia, Bahia, Brazil 060, Brazil (e-mail: [email protected]). Am J Perinatol Rep 2016;6:e299–e300. Abstract There is little information about the congenital chikungunya virus (CHIKV) transmission. We describe two cases of well-documented congenital CHIKV infection in Salvador- Brazil, where CHIKV has been identified since 2014. The outbreak in the city led to the clinical CHIKV diagnoses of both pregnant women 2 days before delivery. Urine and blood samples from the mothers and newborns were collected and tested for reverse transcription-polymerase chain reaction (PCR) analysis for Zika, dengue, and CHIKV. Both neonates and mothers had positive urine and serum PCR results for CHIKV. The Keywords newborns had significant perinatal complications and were admitted to the neonatal ► newborn intensive care unit. The purpose of our case report is to show how severe congenital ► chikungunya CHIKV infection can be and the importance to include CHIKV infection in the differential ► congenital diagnosis of neonatal sepsis when mothers have clinical signs of the disease and live in ► infection an affected area.
    [Show full text]
  • Case Series Newborn Haemorrhagic Disorders: About 30 Cases
    Open Access Case series Newborn haemorrhagic disorders: about 30 cases Brahim El Hasbaoui1,&, Lamia Karboubi1, Badr Sououd Benjelloun1 1Paediatric Medical Emergency Department, Children’s Hospital, Faculty of Medicine and Pharmacy, University Mohammed V, Rabat, Morocco &Corresponding author: Brahim El Hasbaoui, Paediatric Medical Emergency Department, Children’s Hospital, Faculty of Medicine and Pharmacy, University Mohammed V, Rabat, Morocco Key words: New-bornhaemorrhagic disease, vitamin K, breastfeeding Received: 22/06/2017 - Accepted: 05/09/2017 - Published: 18/10/2017 Abstract The haemorrhagic disorders are particularly frequent in neonatal period. Their causes are varied and their knowledge is capital for their good management. Our purpose was to describe the epidemiological, diagnostic, and common causes of new-bornhaemorrhagic syndrome in paediatric emergency medical department of the Rabat Children's Hospital. We conducted a descriptive study from December 2015 to April 2016, about new- borns admitted to medical emergencies for haemorrhagic syndrome defined by bleeding, exteriorized or not, whatever its importance, severity, causes and the associated clinical and biological disorders. Between December 2015 and April 2016, we identified 30 cases of newborn haemorrhagic syndromes on 594 hospitalizations (5.05%). The sex-ratio (M/F) was 1.5. None of them received vitamin K after birth and all were breastfed. Preterm infants accounted for 10%. The presentation of haemorrhage encountered was dominated by visceral bleeding especially digestive (80%), followed by epistaxis (10%), Haematuria (7%), and skin haemorrhage (3%). Physical examination was normal in most of cases with exception (nine babies had pallor with hypotonia, three babies suffered from hypovolemic shock, respiratory distress(10%), drowsiness, poor sucking and fever.
    [Show full text]
  • Subset of Alphabetical Index to Diseases and Nature of Injury for Use with Perinatal Conditions (P00-P96)
    Subset of alphabetical index to diseases and nature of injury for use with perinatal conditions (P00-P96) SUBSET OF ALPHABETICAL INDEX TO DISEASES AND NATURE OF INJURY FOR USE WITH PERINATAL CONDITIONS (P00-P96) Conditions arising in the perinatal period Conditions arising—continued - abnormal, abnormality—continued Note - Conditions arising in the perinatal - - fetus, fetal period, even though death or morbidity - - - causing disproportion occurs later, should, as far as possible, be - - - - affecting fetus or newborn P03.1 coded to chapter XVI, which takes - - forces of labor precedence over chapters containing codes - - - affecting fetus or newborn P03.6 for diseases by their anatomical site. - - labor NEC - - - affecting fetus or newborn P03.6 These exclude: - - membranes (fetal) Congenital malformations, deformations - - - affecting fetus or newborn P02.9 and chromosomal abnormalities - - - specified type NEC, affecting fetus or (Q00-Q99) newborn P02.8 Endocrine, nutritional and metabolic - - organs or tissues of maternal pelvis diseases (E00-E99) - - - in pregnancy or childbirth Injury, poisoning and certain other - - - - affecting fetus or newborn P03.8 consequences of external causes (S00-T99) - - - - causing obstructed labor Neoplasms (C00-D48) - - - - - affecting fetus or newborn P03.1 Tetanus neonatorum (A33) - - parturition - - - affecting fetus or newborn P03.9 - ablatio, ablation - - presentation (fetus) (see also Presentation, - - placentae (see also Abruptio placentae) fetal, abnormal) - - - affecting fetus or newborn P02.1
    [Show full text]
  • Ratified by Hoc/WHO at Hoc Meeting in Cologne, October 2003 92
    Ratified by HoC/WHO at HoC Meeting in Cologne, October 2003 - - amino-acid, neonatal, transitory P74.8 - - coagulation (factor) - - - antepartum with hemorrhage, maternal, affecting fetus or newborn P02.1 - - - newborn, transient P61.6 - - digestive (system), fetus or newborn P78.9 - - - specified NEC P78.8 - - feeding, newborn P92.9 - - fetus or newborn P96.9 - - - specified NEC P96.8 - - hematological, fetus or newborn P61.9 - - - specified NEC P61.8 - - hemorrhagic NEC, newborn P53 - - integument, fetus or newborn P83.9 - - - specified NEC P83.8 - - membranes or fluid, amniotic, affecting fetus or newborn P02.9 - - muscle tone, newborn P94.9 - - - specified NEC P94.8 - - seizure, newborn P90 - - skin, fetus or newborn P83.9 - - - specified NEC P83.8 - - temperature regulation, fetus or newborn P81.9 - - - specified NEC P81.8 - - thyroid (gland) function NEC, neonatal, transitory P72.2 - disproportion (fetopelvic), affecting fetus or newborn P03.1 - distortion (congenital) lumbar spine, maternal - - with disproportion, affecting fetus or newborn P03.1 - distress - - cardiac - - - congenital P20.9 - - - newborn P29.8 - - cardiopulmonary, newborn P96.8 - - cardiorespiratory, newborn P96.8 - - circulatory, newborn P96.8 - - fetal (syndrome) P20.- - - - first noted - - - - before onset of labor P20.0 - - - - during labor and delivery P20.1 - - intrauterine - see Conditions originating in the perinatal period, distress, fetal - - respiratory, newborn P22.9 - - - specified NEC P22.8 - disturbance - see also Conditions originating in the perinatal
    [Show full text]
  • ICD-10-Mortality Perinatal Subset - 2017
    ICD-10-Mortality Perinatal Subset - 2017 Subset of alphabetical index to diseases and nature of injury for use with perinatal conditions (P00-P96) Conditions arising in the perinatal period Note - Conditions arising in the perinatal period, even though death or morbidity occurs later, should, as far as possible, be coded to chapter XVI, which takes precedence over chapters containing codes for diseases by their anatomical site. These exclude: Congenital malformations, deformations and chromosomal abnormalities (Q00-Q99) Endocrine, nutritional and metabolic diseases (E00-E99) Injury, poisoning and certain other consequences of external causes (S00-T99) Neoplasms (C00-D48) Tetanus neonatorum (A33 2a ) A - ablatio, ablation - - placentae (see also Abruptio placentae) - - - affecting fetus or newborn P02.1 2a - abnormal, abnormality, abnormalities - see also Anomaly - - alphafetoprotein - - - maternal, affecting fetus or newborn P00.8 - - amnion, amniotic fluid - - - affecting fetus or newborn P02.9 - - anticoagulation - - - newborn (transient) P61.6 - - cervix NEC, maternal (acquired) (congenital), in pregnancy or childbirth - - - causing obstructed labor - - - - affecting fetus or newborn P03.1 - - chorion - - - affecting fetus or newborn P02.9 - - coagulation - - - newborn, transient P61.6 - - fetus, fetal - - - causing disproportion - - - - affecting fetus or newborn P03.1 - - forces of labor - - - affecting fetus or newborn P03.6 - - labor NEC - - - affecting fetus or newborn P03.6 - - membranes (fetal) - - - affecting fetus or newborn
    [Show full text]